MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

NEOG

9.17

-1.5%↓

Search

Simulations Plus Inc

Geschlossen

BrancheGesundheitswesen

19.89 6.19

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

18.6

Max

20.02

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.4M

676K

Verkäufe

961K

18M

KGV

Branchendurchschnitt

48.528

87.826

EPS

-0.034

Dividendenrendite

0.48

Gewinnspanne

3.67

Angestellte

212

EBITDA

-3M

2.3M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+0.48% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.48%

2.26%

Nächstes Ergebnis

2. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

13M

381M

Vorheriger Eröffnungskurs

13.7

Vorheriger Schlusskurs

19.89

Nachrichtenstimmung

By Acuity

50%

50%

183 / 361 Ranking in Healthcare

Simulations Plus Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Jan. 2026, 19:05 UTC

Wichtige Markttreiber

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13. Jan. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13. Jan. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Jan. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13. Jan. 2026, 23:13 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13. Jan. 2026, 23:10 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13. Jan. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13. Jan. 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13. Jan. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13. Jan. 2026, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13. Jan. 2026, 21:08 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13. Jan. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13. Jan. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13. Jan. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13. Jan. 2026, 19:08 UTC

Akquisitionen, Fusionen, Übernahmen

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13. Jan. 2026, 19:03 UTC

Ergebnisse

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13. Jan. 2026, 18:50 UTC

Ergebnisse

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13. Jan. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13. Jan. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13. Jan. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13. Jan. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer-Vergleich

Kursveränderung

Simulations Plus Inc Prognose

Kursziel

By TipRanks

0.48% Vorteil

12-Monats-Prognose

Durchschnitt 19 USD  0.48%

Hoch 19 USD

Tief 19 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Simulations Plus Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

2

Buy

3

Halten

0

Sell

Stimmung

By Acuity

183 / 361 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat